



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Anti-NA, Neuraminidase [NA-22] Standard Size Ab04394-10.3

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This is a reformatted human IgG1 Fc Silent Fc Silent™ antibody, based on the original human IgG1 format, created for improved compatibility with existing reagents, assays and techniques.

Isotype and Format: Human IgG1, Fc Silent™, Lambda

Clone Number: NA-22

Alternative Name(s) of Target: EC:3.2.1.18

UniProt Accession Number of Target Protein: S5MF06

Published Application(s): crystallography, inhibition, SPR, ELISA

Published Species Reactivity: Influenza A virus

Immunogen: The original antibody was raised by taking B cells from influenza A survivors and vaccinees and immortalizing these.

Specificity: This antibody is specific for the interface between adjacent NA monomers outside of the active site neuraminidase from influenza A.

Application Notes: The structure of the original version of this antibody was determined using cryo-EM and x-ray crystallography (Zhu et al., 2020; PMID:31757767) (Gilchuk et al., 2019; PMID:31757769). This antibody was used for an ELISA on the NA protein of influenza A (Gilchuk et al., 2019; PMID:31757769). The binding strength of this antibody to neuraminidase of influenza A was determined using surface plasmon resonance. This antibody was used for an egress inhibition assay on MDCK cells infected with influenza A. Here it showed its ability to inhibit egress at low concentrations (Gilchuk et al., 2019; PMID:31757769). This antibody was used for a HDX-MS study. The N9 antigen showed hydrogen-deuterium exchange in the presence of this antibody (Gilchuk et al., 2019; PMID:31757769). This antibody was used for a fetuin-based ELLA NA activity assay. Here it showed inhibition of NA (Zhu et al., 2020; PMID:31757767).

Antibody First Published in: Gilchuk et al. Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in Mice Cell Host Microbe. 2019 Dec 11;26(6):715-728.e8 [PMID:31757769](#)

Note on publication: The original paper isolated 35 human monoclonal antibodies (mAbs) from two H7N9 survivors and two vaccinees.

Product Form

Size: 100 µg Purified antibody.

Purification: Protein A affinity purified

Supplied In: PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.